Rakesh Dixit
President & Chief Executive Officer Bionavigen Oncology
Seminars
• Weighing up cost, time and predictive value across CDX, PDX and in vitro models for ADCs
• Establishing preclinical biomarkers to bridge ADC clinical development
• Debating translational considerations for bispecific ADCs and combinations to best predict clinical activity
- Contextualizing concepts from emerging novel conjugates: Dual payload ADCs and bispecific ADCs
- Considering factors for balancing DAR and combining mechanisms for dual payload toxicity profiles
- Evaluating the ongoing development and promise of bispecific ADC programs
Download the Full Event Guide for full details
Despite blockbuster ADCs moving to earlier-line treatments and challenging oncology standard of care, poor tolerability remains the limiting factor to widen therapeutic index and achieve true success in patients.
Don’t miss this seminar day utilizing in vivo and in vitro models to predict ADC clinical safety profiles, characterizing and mitigating on and off-target ADC toxicities, and spotlighting ADC design with enhanced tolerability profiles
Download the Full Event Guide for full details
